Brazil Launches Pilot Single-Dose Dengue Vaccination in Three Cities

Overview

• Maranguape (CE) and Nova Lima (MG) began vaccinations on January 17, with Botucatu (SP) joining on January 18 as part of a federal real‑world effectiveness study.
• The campaign uses Instituto Butantan’s Anvisa‑approved Butantan‑DV, the world’s first single‑dose dengue vaccine, with trials showing about 74–75% overall efficacy, over 91% against severe disease, and no hospitalizations among vaccine recipients.
• Pilot eligibility is people aged 15 to 59, with municipal guidance excluding groups such as pregnant or immunosuppressed individuals and those with a recent dengue infection.
• An initial 204,100 doses were allocated for the first stage: 80,000 to Botucatu, 60,100 to Maranguape, and 64,000 to Nova Lima to cover the target populations.
• Local drives include Day D events, UBS clinics, mobile and drive‑thru sites with free vaccination via SUS, and authorities project up to 30 million doses by the second half of 2026 to support national expansion.